Recursion Pharmaceuticals, Inc. (RXRX) Operating income 2019–2025
Recursion Pharmaceuticals, Inc. (RXRX) annual operating income history from SEC filings — each fiscal year as reported.
-$648.1MFY2025 · since FY2019: -$62.4M → -$648.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$648.1M | -35.3% |
| FY2024 | -$479.0M | -36.8% |
| FY2023 | -$350.1M | -42.5% |
| FY2022 | -$245.7M | -34.4% |
| FY2021 | -$182.8M | -116.0% |
| FY2020 | -$84.6M | -35.5% |
| FY2019 | -$62.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More RXRX financial trends
RXRX RevenueRXRX Net incomeRXRX Net marginRXRX Gross profitRXRX Gross marginRXRX Operating marginRXRX Operating cash flowRXRX Free cash flowRXRX Capital expendituresRXRX Return on equityRXRX Stock buybacksRXRX Dividends paidRXRX Total assetsRXRX Total liabilitiesRXRX Shareholders’ equityRXRX overview →